Convatec Dividends - CTEC

Convatec Dividends - CTEC

Best deals to access real time data!
Level 2 Basic
Monthly Subscription
for only
Monthly Subscription
for only
UK/US Silver
Monthly Subscription
for only
VAT not included
Stock Name Stock Symbol Market Stock Type Stock ISIN Stock Description
Convatec Group Plc CTEC London Ordinary Share GB00BD3VFW73 ORD 10P
  Price Change Price Change % Stock Price Last Trade
0.20 0.09% 222.80 14:13:45
Open Price Low Price High Price Close Price Previous Close
221.40 219.90 223.10 222.60
more quote information »
Industry Sector

Convatec CTEC Dividends History

Announcement Date Type Currency Dividend Amount Period Start Period End Ex Date Record Date Payment Date Total Dividend Amount

Top Dividend Posts

thewheeliedealer: Hi all, My mate Peter @Conkers3 and myself did a ‘Twin Petes Investing’ Podcast last week and part of our discussion includes CTEC which we both see as a decent and solid Long-Term Hold kind of Stock. As always we also chatted about loads of other Stocks and Ideas for research and a fair bit of educational stuff with regards to Investing and Portfolio Management. Specific topics in this one include the risks of anonymous Twitter Accounts and the devious tricks the ‘owners’ get up to, and we give examples of our own Trades and how we have Scaled in and Scaled out etc. Anyway, if you use Youtube, Apple, Audioboom, Overcast, Google+ or Spotify you can find it under the 'Conkers Corner' Channel (you want Podcast TPI 44) and you can find it on Soundcloud at the link below. I hope you enjoy it and find it useful, we try to keep them light and they are totally unscripted, with the intent being that it is like you are eavesdropping on us having a chat down the local boozer (we can dream !!). Cheers, WD @wheeliedealer hTTps://
robow: CTEC is one of Shares magazine top picks for 2021. In brief - the business is looking healthier after rectifing earlier mistakes and earnings growth is back on the menu
doubleorquits: Indeed, although I feel it may lose out to Kingfisher in the final furlong. The top four to replace the losers highlighted in The Observer are AVST,GVC,HSV and KGF at the moment although it is close between the latter and CTEC (I think all the others are safer bets). Review actually takes place at the close on Tuesday and changes become confirmed on Monday 22nd June. The following site is an excellent reference point for this: hTTp:// NB: All five might go in if ITV loses a bit more ground in the next three days.
hootstox: Getting some coverage about FTSE100 changeover, CTEC could move up on Friday
robow: CTEC gets a mention in todays Times Convatec could be a comfort in old age. 'there could be rewards ahead...BUY'
robow: from Citywire 26 Mar 19 AJ Bell: Convatec in need of a shake-up A management shake-up at medical equipment maker Convatec (CTEC) could be the start of a new way of thinking that could benefit investors, says AJ Bell. Convatec has poached Genus’ boss Karim Bitar to be its new chief executive to lead its turnaround effort just as the former is also losing its chairman and deputy chairman. ‘Convatec desperately needs a new lease of life as it has been a serial disappointment for most of its time as a listed business,’ said analyst Russ Mould. Last month, the group announced plans to invest $150 million over three years and Mould said ‘the scale of such investment was significantly greater than expected, despite having scope to deliver $120 million in annual savings by 2023, as well as improvements in revenue growth and profit margins’.
robow: One of Peel Hunt's stock picks for 2019 Convatec (CTEC) The depressed share price at medical products company Convatec has led to a rise in the dividend yield but the poor sentiment is unfounded. Analyst Amy Walker retained her ‘hold’ recommendation and target price of 170p on the stock. She said that ‘low visibility on earnings momentum has depressed the share price, leading to a rise in the dividend yield’ but even if the group misses her ‘conservative’ growth forecasts by 7% to 11% the company could still ‘yield at least 3% at the current share price, at the bottom of its target pay-out range’. Walker is not pessimistic about the outlook for the company, stating that the demand for the medical technology firm’s products were ‘unlikely to change materially from their mid-single digit market growth rates’. She added that the company can ‘support a stable to growing dividend’ but the most likely driver of volatility is the share price ‘which declined more than 30% on the most recent profit warning’.
philanderer: Numis upgrades Convatec to ‘buy’ Numis has upgraded medical technology company Convatec (CTEC) after an ‘unwarranted’ 35% fall in the share price. Analyst Paul Cuddon upgraded his recommendation from ‘hold’ to ‘buy’ with a target price of 220p on the shares, which jumped 5.6% to 155p yesterday. ‘We do not think the loss of a chief executive and the decline in infusion devices warranted a 35% fall in Convatec’s share price, especially when the broader chronic care business is maintaining consistent 2% quarterly growth,’ he said. ‘We see full-year 2018 results, details on the self-help strategy and full-year 2019 outlook as key catalysts. The company trades on 10x enterprise value/earnings and offering sector leading free cashflow yield and so we upgrade to “buy”.’ HTTPS://
cantrememberthis2: Despite the warning and its cautious stance on the stock, RBC said the share price reset has gone too far and highlighted the fact that Convatec is still a cash generative business with attractive qualities. "We would remind investors that Convatec is still a highly cash generative business, and at the current share price is generating a free cash flow yield of over 7%, with a dividend yield of 3%," it said. "With the performance wanting we would hope all options are now on the table to maximise shareholder value."
douglas fir: Trading update for the three months ended 30 September 2018 and change in FY 2018 guidance 15 October, 2018 (LSE: CTEC) The revised guidance is driven primarily by a change in inventory policy by the biggest customer in our Infusion Devices franchise, which is expected to have a material negative impact on revenue in the fourth quarter of between $18 - $23 million, and to a lesser extent challenging market dynamics in specific markets in Advanced Wound Care.
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210513 13:30:03